Prevention and treatment of experimental autoimmune encephalomyelitis with clonotypic CDR3 peptides: CD4+ FoxP3+ T-regulatory cells suppress interleukin-2-dependent expansion of myelin basic protein-specific T cells

Immunology

Volumn 130, Issue 1, 2010, Pages 114-124

  Buenafe, Abigail C ^a   Andrew, Shayne ^b   Afentoulis, Michael ^c   Offner, Halina ^a,b   Vandenbark, Arthur A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c Providence Cancer Center   (United States)

Author keywords

Experimental autoimmune encephalomyelitis (EAE); Foxp3; T regulatory (Treg); T cell receptor (TCR) peptide; Therapy

Indexed keywords

FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN 85-99; TCR CDR3 PEPTIDE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; THERAPY EFFECT; TRANSGENIC MOUSE;

ANIMALS; CELL SEPARATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; MYELIN BASIC PROTEINS; PEPTIDE FRAGMENTS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 77950476971     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03218.x     Document Type: Article

References (51)

1. Olerup O, Hillert J. HLA class II-associated genetic susceptibility to multiple sclerosis: a critical evaluation. Tissue Antigens 1991 38 : 1 15.
2. Haines JL, Ter-Minassian M, Bazyk A et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. The Multiple Sclerosis Genetics Group. Nat Genet 1996 13 : 469 471.
3. Sawcer S, Jones HB, Feakes R et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996 13 : 464 468.
4. Ebers GC, Kukay K, Bulman DE et al. A full genome search in multiple sclerosis. Nat Genet 1996 13 : 472 476.
5. Hauser SL, Fleischnick E, Weiner HL, Marcus D, Awdeh Z, Yunis EJ, Alper CA. Extended major histocompatibility haplotypes in patients with multiple sclerosis. Neurology 1989 39 : 275 277.
6. Seboun E, Robinson MA, Doolittle TH, Ciulla TA, Kindt JJ, Hauser SL. A susceptibility locus for multiple sclerosis is linked to the T cell receptor chain complex. Cell 1989 57 : 1095 1100.
7. Ghabanbasani MZ, Gu XX, Spaepen M, Vandevyver C, Raus J, Marynen P, Carton H, Cassiman JJ. Importance of HLA-DRB1 and DQA1 genes and of the amino acid polymorphisms in the functional domain of DRB1 chain in multiple sclerosis. J Neuroimmunol 1995 59 : 77 82.
8. Ota K, Matsui M, Milford EL, Macklin GA, Weiner HL, Hafler DA. T cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990 346 : 183 185.
9. Sun JB, Olsson T, Wang WZ, Xiao BG, Kostulas V, Fredrikson S, Ekre HP, Link H. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991 21 : 1461 1468.
10. Chou YK, Bourdette DN, Offner H, Whitham R, Wang R, Hashim GA, Vandenbark AA. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 1992 38 : 105 114.
11. Kerlero-de-Rosbo N, Ben-Nun A. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. J Autoimmun 1998 11 : 287 299.
12. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994 179 : 973 984.
13. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992 358 : 155 157.
14. Miller SD, Karpus WJ. The immunopathogenesis and regulation of T-cell mediated demyelinating diseases. Immunol Today 1994 15 : 356 361.
15. Madsen LS, Andersson EC, Jansson L et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 1999 23 : 343 347.
16. Cohen IR, Young DB. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today 1991 12 : 105 110.
17. Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989 341 : 541 544.
18. Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 1989 246 : 668 670.
19. Jiang H, Sercarz E, Nitecki D, Pernis B. The problem of presentation of T cell receptor peptides by activated T cells. Ann NY Acad Sci 1991 636 : 28 32.
20. Vandenbark AA, Hashim G, Offner H. T cell receptor peptides in treatment of autoimmune disease: rationale and potential. J Neurosci Res 1996 43 : 391 402.
21. Kumar V. Homeostatic control of immunity by TCR peptide-specific Tregs. J Clin Invest 2004 114 : 1222 1226.
22. Offner H, Hashim G, Vandenbark AA. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 1991 251 : 430 432.
23. Kumar V, Coulsell E, Ober B, Hubbard G, Sercarz E, Ward ES. Recombinant T cell receptor molecules can prevent and reverse experimental autoimmune encephalomyelitis. J Immunol 1997 159 : 5150 5156.
24. Rosloniec EF, Brand DD, Whittington KB, Stuart JM, Ciubotaru M, Ward ES. Vaccination with a recombinant Va domain of a TCR prevents the development of collagen-induced arthritis. J Immunol 1995 155 : 4504 4511.
25. Elias D, Tikochinski Y, Frankel G, Cohen IR. Regulation of NOD mouse autoimmune diabetes by T cells that recognize a TCR CDR3 peptide. Int Immunol 1999 11 : 957 966.
26. Vainiene M, Celnik B, Hashim G, Vandenbark AA, Offner H. Natural immunodominant and EAE-protective determinants within the Lewis rat VB8.2 sequence include CDR2 and framework 3 idiotopes. J Neurosci Res 1996 43 : 137 145.
27. Kumar V, Tabibiazar R, Geysen HM, Sercarz E. Immunodominant framework region 3 peptide from TCR VB8.2 chain controls murine experimental autoimmune encephalomyelitis. J Immunol 1995 154 : 1941 1950.
28. Burrows GG, Chou YK, Wang C et al. Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells. J Immunol 2001 167 : 4386 4395.
29. + T cells for self-T cell receptor determinants. J Neurosci Res 2004 76 : 129 140.
30. Vandenbark AA, Chou YK, Whitham R et al. Treatment of multiple sclerosis with T cell receptor peptides: results of a double-blind pilot trial. Nat Med 1996 2 : 1109 1115.
31. Moreland LW, Morgan EE, Adamson TC et al. T cell receptor peptide vaccination in rheumatoid arthritis. A placebo-controlled trial using a combination of Vβ3, Vβ14, and Vβ17 peptides. Arthritis Rheum 1998 41 : 1919 1929.
32. + TCR-specific T cells involves IL-4, IL-10 and IFN-gamma. Autoimmunity 1999 31 : 237 248.
33. Offner H, Adlard K, Bebo BF, Schuster J, Burrows GG, Buenafe AC, Vandenbark AA. Vaccination with BV8S2 protein amplifies TCR-specific regulation and protection against experimental autoimmune encephalomyelitis in TCR BV8S2 mice. J Immunol 1998 161 : 2178 2186.
34. Hafler DA, Saadeh MG, Kuchroo VK, Milford E, Steinman L. TCR usage in human and experimental demyelinating disease. Immunol Today 1996 17 : 152 159.
35. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999 162 : 5317 5326.
36. Apostolou I, Verginis P, Kretschmer K, Polansky J, Huhn J, von Boehmer H. Peripherally induced Treg: mode, stability, and role in specific tolerance. J Clin Immunol 2008 28 : 619 624.
37. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003 198 : 1875 1886.
38. Vandenbark AA, Offner H. Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored? Immunology 2008 125 : 1 13.
39. Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology 2008 124 : 13 22.
40. + regulatory T cells. Immunol Rev 2006 212 : 60 73.
41. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006 212 : 8 27.
42. + T cells for IL-2 and exploit it for the induction of IL-10 production. Int Immunol 2005 17 : 279 288.
43. + regulatory T cell function. Eur J Immunol 2004 34 : 2480 2488.
44. + T cells. Nat Immunol 2007 8 : 1353 1362.
45. Scheffold A, Murphy KM, Hofer T. Competition for cytokines: T(reg) cells take all. Nat Immunol 2007 8 : 1285 1287.
46. + T regulatory cells. Nat Immunol 2003 4 : 337 342.
47. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003 299 : 1057 1061.
48. + regulatory T cells. Nat Immunol 2003 4 : 330 336.
49. Huan J, Culbertson N, Spencer L et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005 81 : 45 52.
50. + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004 199 : 971 979.
51. Vandenbark AA, Culbertson NE, Bartholomew RM et al. Therapeutic vaccination with a trivalent T cell receptor peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 2008 123 : 66 78.